<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Bioengagement &#187; Biotechnology</title>
	<atom:link href="http://www.bioengagement.com/category/biotech/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.bioengagement.com</link>
	<description>Making Commercial Successes Out of Life Science Innovations</description>
	<lastBuildDate>Wed, 26 Oct 2011 11:17:40 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=291</generator>
<xhtml:meta xmlns:xhtml="http://www.w3.org/1999/xhtml" name="robots" content="noindex" />
		<item>
		<title>As Biotech Shifts Gear What Does It Mean For Fee-For-Service Providers?</title>
		<link>http://www.bioengagement.com/biotech/as-biotech-shifts-gear-what-does-it-mean-for-fee-for-service-providers/</link>
		<comments>http://www.bioengagement.com/biotech/as-biotech-shifts-gear-what-does-it-mean-for-fee-for-service-providers/#comments</comments>
		<pubDate>Tue, 09 Nov 2010 15:26:33 +0000</pubDate>
		<dc:creator>Karen</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Lifescience]]></category>
		<category><![CDATA[Marketing Strategy]]></category>
		<category><![CDATA[Clinical Research Organization]]></category>
		<category><![CDATA[Clinical trials]]></category>
		<category><![CDATA[drug delivery technology]]></category>
		<category><![CDATA[venture capital funding]]></category>

		<guid isPermaLink="false">http://www.bioengagement.com/?p=350</guid>
		<description><![CDATA[As biotech/pharma adapt to the changing climate, what does this mean for the technology and service providers that support them?]]></description>
			<content:encoded><![CDATA[<p>
Yesterday&#8217;s publication of PriceWaterhouseCooper&#8217;s evaluation of the biotechnology industry provides some sobering reading.  Amongst the doom and gloom there&#8217;s promise and some pointers for where this industry&#8217;s service providers should look for securing and growing <a href='http://www.bioengagement.com/biotech/as-biotech-shifts-gear-what-does-it-mean-for-fee-for-service-providers/' rel="nofollow">Read more...</a></p>]]></content:encoded>
			<wfw:commentRss>http://www.bioengagement.com/biotech/as-biotech-shifts-gear-what-does-it-mean-for-fee-for-service-providers/feed/</wfw:commentRss>
		<slash:comments>2</slash:comments>
		</item>
		<item>
		<title>Twitter for Biotechs? Not Just a PR Machine&#8230;</title>
		<link>http://www.bioengagement.com/biotech/twitter-for-biotechs-not-just-a-pr-machine/</link>
		<comments>http://www.bioengagement.com/biotech/twitter-for-biotechs-not-just-a-pr-machine/#comments</comments>
		<pubDate>Thu, 14 Oct 2010 12:02:24 +0000</pubDate>
		<dc:creator>Karen</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Communications]]></category>
		<category><![CDATA[lead generation]]></category>
		<category><![CDATA[Lifescience]]></category>
		<category><![CDATA[marketing channel]]></category>
		<category><![CDATA[marketing tactics]]></category>
		<category><![CDATA[sales leads]]></category>
		<category><![CDATA[social media]]></category>
		<category><![CDATA[Twitter]]></category>

		<guid isPermaLink="false">http://www.bioengagement.com/?p=308</guid>
		<description><![CDATA[Tweetdeck can be like your kitchen table - full of good things but in a bit of a mess.  Use the free tools provided and you can leverage Twitter not just for PR purposes, but for generating new business leads as well.]]></description>
			<content:encoded><![CDATA[<p>
I was absent-mindedly driving my children to school yesterday with one ear on the radio when that otherwise irritating &#8220;Thought For The Day&#8221; came on.  Normally I&#8217;d switch off at this point as I hate pious witterings first thing in the morning (or anytime, come to think of it) <a href='http://www.bioengagement.com/biotech/twitter-for-biotechs-not-just-a-pr-machine/' rel="nofollow">Read more...</a></p>]]></content:encoded>
			<wfw:commentRss>http://www.bioengagement.com/biotech/twitter-for-biotechs-not-just-a-pr-machine/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
		</item>
		<item>
		<title>How Critical Pharmaceuticals Gained £1.5M Funding During the Credit Crisis</title>
		<link>http://www.bioengagement.com/biotech/how-critical-pharmaceuticals-gained-1-5m-funding-during-the-credit-crisis/</link>
		<comments>http://www.bioengagement.com/biotech/how-critical-pharmaceuticals-gained-1-5m-funding-during-the-credit-crisis/#comments</comments>
		<pubDate>Wed, 25 Nov 2009 15:22:23 +0000</pubDate>
		<dc:creator>Karen</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[drug delivery technology]]></category>
		<category><![CDATA[investment strategy]]></category>
		<category><![CDATA[Investor pitch]]></category>
		<category><![CDATA[Start-Up]]></category>
		<category><![CDATA[venture capital funding]]></category>

		<guid isPermaLink="false">http://bioengagement.wordpress.com/?p=77</guid>
		<description><![CDATA[When VC funding streams dry up, seek alternatives.  Here's one biotech's success story.]]></description>
			<content:encoded><![CDATA[<p>For young biotechnology companies, attracting seed and early stage funding has become increasingly difficult this year although anecdotal signs of recovery are beginning to emerge.
The main reason: venture capital funds have been focusing on their existing portfolio companies who were holding off <a href='http://www.bioengagement.com/biotech/how-critical-pharmaceuticals-gained-1-5m-funding-during-the-credit-crisis/' rel="nofollow">Read more...</a></p>]]></content:encoded>
			<wfw:commentRss>http://www.bioengagement.com/biotech/how-critical-pharmaceuticals-gained-1-5m-funding-during-the-credit-crisis/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
		</item>
	</channel>
</rss>

